Cargando…

Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma

Development of drug resistance limits the efficacy of targeted therapies. Alternative approaches using different combinations of therapeutic agents to inhibit several pathways could be a more effective strategy for treating cancer. The effects of the approved epidermal growth factor receptor (EGFR)-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jeannot, Victor, Busser, Benoit, Vanwonterghem, Laetitia, Michallet, Sophie, Ferroudj, Sana, Cokol, Murat, Coll, Jean-Luc, Ozturk, Mehmet, Hurbin, Amandine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108607/ https://www.ncbi.nlm.nih.gov/pubmed/27877053 http://dx.doi.org/10.2147/OTT.S117743

Ejemplares similares

Stapled peptide targeting the CDK4/Cyclin D interface combined with Abemaciclib inhibits KRAS mutant lung cancer growth
por: Bouclier, Celine, et al.
Publicado: (2020)

Verteporfin-Loaded Lipid Nanoparticles Improve Ovarian Cancer Photodynamic Therapy In Vitro and In Vivo
por: Michy, Thierry, et al.
Publicado: (2019)

Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells
por: Adjibade, Pauline, et al.
Publicado: (2015)

Identification of pyrrolopyrimidine derivative PP-13 as a novel microtubule-destabilizing agent with promising anticancer properties
por: Gilson, Pauline, et al.
Publicado: (2017)

Sorafenib resistance in hepatocarcinoma: role of hypoxia-inducible factors
por: Méndez-Blanco, Carolina, et al.
Publicado: (2018)

Thioredoxin Downregulation Enhances Sorafenib Effects in Hepatocarcinoma Cells
por: López-Grueso, María José, et al.
Publicado: (2019)

Regulation of the sensitivity of hepatocarcinoma cells by ORMDL3, to sorafenib by autophagy
por: Sun, Yixiao, et al.
Publicado: (2022)

Guided screen for synergistic three-drug combinations
por: Cokol-Cakmak, Melike, et al.
Publicado: (2020)

Synergistic effects of vorinostat (SAHA) and azoles against Aspergillus species and their biofilms
por: Tu, Bo, et al.
Publicado: (2020)

The Synergistic Effects of 5-Aminosalicylic Acid and Vorinostat in the Treatment of Ulcerative Colitis
por: He, Long, et al.
Publicado: (2021)

Vorinostat—An Overview
por: Bubna, Aditya Kumar
Publicado: (2015)

Chemogenomic model identifies synergistic drug combinations robust to the pathogen microenvironment
por: Cokol, Murat, et al.
Publicado: (2018)

YRDC Mediates the Resistance of Lenvatinib in Hepatocarcinoma Cells via Modulating the Translation of KRAS
por: Guo, Jun, et al.
Publicado: (2021)

Phospholipase D1 is upregulated by vorinostat and confers resistance to vorinostat in glioblastoma
por: Kang, Dong Woo, et al.
Publicado: (2020)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Regulation of Multidrug Resistance Proteins by Genistein in a Hepatocarcinoma Cell Line: Impact on Sorafenib Cytotoxicity
por: Rigalli, Juan Pablo, et al.
Publicado: (2015)

Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer
por: Han, Ji-Youn, et al.
Publicado: (2015)

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double‐positive lung cancer
por: Takeuchi, Shinji, et al.
Publicado: (2020)

Synergistic effect of gefitinib and rofecoxib in mesothelioma cells
por: Stoppoloni, Daniela, et al.
Publicado: (2010)

Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment
por: Borgia, Francesco, et al.
Publicado: (2017)

Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib
por: Fondevila, Flavia, et al.
Publicado: (2021)

Vorinostat in solid and hematologic malignancies
por: Siegel, David, et al.
Publicado: (2009)

Antioxidants Impair Anti-Tumoral Effects of Vorinostat, but Not Anti-Neoplastic Effects of Vorinostat and Caspase-8 Downregulation
por: Bergadà, Laura, et al.
Publicado: (2014)

Vorinostat (SAHA) and Breast Cancer: An Overview
por: Wawruszak, Anna, et al.
Publicado: (2021)

Synergistic Anticancer Effects of Vorinostat and Epigallocatechin-3-Gallate against HuCC-T1 Human Cholangiocarcinoma Cells
por: Kwak, Tae Won, et al.
Publicado: (2013)

Stabilization of Hypoxia-Inducible Factors and BNIP3 Promoter Methylation Contribute to Acquired Sorafenib Resistance in Human Hepatocarcinoma Cells
por: Méndez-Blanco, Carolina, et al.
Publicado: (2019)

Plasma Circulating Tumor DNA Levels for the Monitoring of Melanoma Patients: Landscape of Available Technologies and Clinical Applications
por: Busser, Benoit, et al.
Publicado: (2017)

Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer
por: Zou, Zheng-Zhi, et al.
Publicado: (2015)

MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma
por: Wei, Xufu, et al.
Publicado: (2015)

Clinical Efficacy of Vorinostat in a Patient with Leiomyosarcoma
por: Lee, Jin, et al.
Publicado: (2012)

The Effect of Vorinostat on the Development of Resistance to Doxorubicin in Neuroblastoma
por: Lautz, Timothy B., et al.
Publicado: (2012)

Immune effectors required for the therapeutic activity of vorinostat
por: Kepp, Oliver, et al.
Publicado: (2013)

Differential Response of Mycosis Fungoides Cells to Vorinostat
por: Bordeaux, Zachary A., et al.
Publicado: (2023)

Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells
por: Gu, Ha Ra, et al.
Publicado: (2015)

Photodynamic Diagnosis and Therapy for Peritoneal Carcinomatosis: Emerging Perspectives
por: Xu, Si, et al.
Publicado: (2020)

A Recombinant Fungal Lectin for Labeling Truncated Glycans on Human Cancer Cells
por: Audfray, Aymeric, et al.
Publicado: (2015)

MiR-338-3p Inhibits Hepatocarcinoma Cells and Sensitizes These Cells to Sorafenib by Targeting Hypoxia-Induced Factor 1α
por: Xu, Haitao, et al.
Publicado: (2014)

Vorinostat and quinacrine have synergistic effects in T-cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition
por: Jing, Bo, et al.
Publicado: (2018)

Synergistic silencing of α-globin and induction of γ-globin by histone deacetylase inhibitor, vorinostat as a potential therapy for β-thalassaemia
por: Mettananda, Sachith, et al.
Publicado: (2019)

Cocktail hepatocarcinoma therapy by a super-assembled nano-pill targeting XPO1 and ATR synergistically
por: Gong, Liuyun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_bt5dbtp5kj6gvqduchbhtfgr6r